by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract INTRODUCTION Blood-based biomarkers (BBMs) can enable early detection of brain amyloid beta (Aβ) pathology in cognitively unimpaired individuals. However, the extent to which common medical conditions affect biomarker performance remains unclear. METHODS...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract Recent research highlights the critical role of inflammation in accelerating amyloid beta and phosphorylated tubulin-associated protein tau cascade and Alzheimer’s disease (AD) progression. Emerging evidence suggests that exercise influences AD by...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract BACKGROUND The diagnostic and prognostic performance of the novel fluid biomarkers brain-derived tau (BD-tau) and phospho-tau217 (p-tau217) in Creutzfeldt–Jakob disease (CJD) is not defined. METHODS We measured cerebrospinal fluid (CSF) and plasma BD-tau,...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract INTRODUCTION We evaluated whether higher Dietary Inflammatory Index (DII) scores were associated with increased incidence of all-cause dementia and Alzheimer’s disease (AD) dementia over 22.3 years of follow-up in the community-based Framingham Heart...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract INTRODUCTION This study presents a novel multi-view learning approach for machine learning (ML)–based Alzheimer’s disease (AD) diagnosis. METHODS A diffusion model is proposed to synthesize the fluorodeoxyglucose positron emission tomography (FDG PET)...
by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia
Abstract INTRODUCTION The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is evaluating lifestyle interventions in older adults at risk for cognitive decline and dementia. Here we characterize the baseline data set of...
